Navigation Links
Auxilium Pharmaceuticals to Present at the Leerink Swann 2012 Global Healthcare Conference
Date:2/1/2012

lts may differ materially from those reflected in these forward-looking statements due to various factors, including further evaluation of clinical data, results of clinical trials, decisions by regulatory authorities as to whether and when to approve drug applications, and general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries and those discussed in Auxilium's Annual Report under the heading "Risk Factors" on Form 10-K for the year ended December 31, 2010 and in Auxilium's Quarterly Report on Form 10-Q for the quarter ended September 30, 2011, which are on file with the Securities and Exchange Commission (the "SEC") and may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov or by means of Auxilium's home page on the Internet at http://www.Auxilium.com under the heading "For Investors -- SEC Filings." There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide Auxilium's expectations, plans or forecasts of future events and views as of the date of this release. Auxilium anticipates that subsequent events and developments will cause Auxilium's assessments to change. However, while Auxilium may elect to update these forward-looking statements at some point in the future, Auxilium specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Auxilium's assessments as of any date subsequent to the date of this release.

'/>"/>
SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Announces First Patients Dosed in XIAFLEX® Phase Ib Cellulite Study
2. Auxilium Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
3. Auxilium Pharmaceuticals, Inc. Announces First Patient Dosed in XIAFLEX® Study for Frozen Shoulder Syndrome
4. Auxilium Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference
5. Auxilium Pharmaceuticals, Inc. Announces Publication of U.S. CPT® Codes and Related Reimbursement Rates for XIAFLEX®
6. Auxilium Pharmaceuticals to Announce Third Quarter 2011 Results and Conduct Conference Call on Monday, October 31, 2011
7. Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytrens Contracture in E-poster at ASSH Meeting
8. Auxilium Pharmaceuticals Announces Positive Data from Commercial Patient Chart Review in E-posters at ASSH Meeting
9. Auxilium Pharmaceuticals, Inc. Announces Positive Top-Line Results from XIAFLEX® Multi-Cord Study
10. Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX®
11. Auxilium Pharmaceuticals Announces Investor Event to Occur at 2011 ASSH Meeting on September 9, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)...   Royal Philips (NYSE: ... received 510(k) clearance from the U.S. Food and ... for Transcatheter Aortic-Valve Implantation (TAVI) treatments. Through 3D ... pre-procedural, high-precision positioning to treat aortic stenosis ailments.  ... available as part of Philips IntelliSpace Portal ...
(Date:8/21/2014)... JOSE, Calif. , Aug. 21, 2014  SI-BONE, ... medical device company that pioneered the use of the ... (MIS) device indicated for fusion of the sacroiliac (SI) ... ) published an update to its Lumbar Fusion Medical ... SI joint fusion procedure.  The policy states that the ...
(Date:8/21/2014)... 2014   Auxilium Pharmaceuticals, Inc. (NASDAQ: ... today announced positive results from a randomized, double-blind ... CCH) for the treatment of edematous fibrosclerotic panniculopathy ... 2a trial, all three doses of CCH (low ... improvement in the appearance of cellulite as measured ...
Breaking Medicine Technology:Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 2Philips receives FDA 510(k) Clearance for TAVI Precision Treatment Planning Application 3SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 2SI-BONE, Inc. Announces Positive Coverage Decision by Priority Health 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 2Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 3Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 4Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 5Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 6Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite 7
... May 9 Osteoarthritis is a,painful and ... people in the United States. It is ... The novel investigational pain medication,tapentadol, a centrally ... with joint-disease pain, compared to those treated ...
... Biosciences, Inc.,(Nasdaq: RDEA ), a company focused ... for the treatment of HIV, cancer and,inflammatory diseases, ... been appointed Senior Vice President, Finance and Operations ... will resign from our board of,directors shortly thereafter. ...
Cached Medicine Technology:Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 2Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 3Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 4Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 5Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results 6
(Date:8/21/2014)... a new review of seafood safety, Consumer Reports is ... concerns about mercury exposure. "We,re particularly concerned about ... the most commonly eaten seafood in the United States. ... Halloran, director of food policy initiatives for Consumers Union, ... news release from the group. While pregnant women ...
(Date:8/21/2014)... 21, 2014 Pleio, Inc., a ... launching a new suite of services for retail ... retail pharmacy by applying proven behavior shaping programs ... in increased medication adherence, higher PDC scores and ... Pleio’s PDC-targeted offerings align retail’s desire to meet ...
(Date:8/21/2014)... 21, 2014) An international scientific collaboration led by ... alterations that may contribute to a rare form of ... rare cancer but other types as well. , The ... Cancer Genome Atlas initiative , completed the sequence ... today in the journal Cancer Cell . ...
(Date:8/21/2014)... SAN FRANCISCO, Aug. 21, 2014 Individuals with schizophrenia ... goals for themselves, and a new study from San ... difficulty in assessing the amount of effort required to ... published this week in the Journal of Abnormal ... deficits among patients with schizophrenia and help those patients ...
(Date:8/21/2014)... Stevin McNamara’s original approach to guitar music is based ... that has existed in India for centuries. Literally meaning “that ... or some fixed sequence of notes, but is considered a ... time of day or season of the year — it ... occurs, in its turn creating an unique “sound manifestation” between ...
Breaking Medicine News(10 mins):Health News:Consumer Reports Advises Pregnant Women to Avoid Tuna 2Health News:Pleio, Inc. Expands Adherence Offerings For Retail Pharmacy 2Health News:Sequence of rare kidney cancer reveals unique alterations involving telomerase 2Health News:Sequence of rare kidney cancer reveals unique alterations involving telomerase 3Health News:Difficulty assessing effort drives motivation deficits in schizophrenia, study finds 2Health News:Raga Cycle of Shakti Guitar Follows The Sun 2Health News:Raga Cycle of Shakti Guitar Follows The Sun 3
... The Michael J. Fox,Foundation (MJFF) for Parkinson,s Research ... effort. Under this annual program the Foundation,will award ... designed to validate the,therapeutic potential of scientific discoveries, ... investment and clinical trials., "Target Validation is ...
... cells in the liver, allowing steatosis (simple fatty liver) ... to the results of a new study in the ... Wiley & Sons on behalf of the American Association ... is also available online at Wiley Interscience (http://www.interscience.wiley.com/journal/hepatology). , ...
... Carrington,Laboratories, Inc. (OTC Bulletin Board: CARN) today ... present,at the Acumen BioFin Rodman & Renshaw 9th ... pm Eastern Time at the New York Palace,Hotel. ... technologies in the,areas of drug delivery and vaccine ...
... NEW YORK, Nov. 1 Fibromyalgia is the ... States, affecting more than,six million Americans. But, findings ... Association (NFA) show there is still much to ... of the general public shows nearly half (45%) ...
... ... Services, DALLAS, Nov. 1 ... the largest gift in the,institution,s 80-year history. The Schenkels, gift today represents ... Schenkels, $4 million gift, the fund now tops the $50,million mark. ...
... is common in children with heart disease, a population ... , More than 25 percent of children with ... say researchers from The Childrens Hospital of Philadelphia and ... current issue of Pediatrics. While this 25 percent prevalence ...
Cached Medicine News:Health News:Michael J. Fox Foundation Commits Up to $2 Million for PD Drug Development Under Target Validation 2008 2Health News:High-fat diet makes mice susceptible to liver injury 2Health News:Carrington Subsidiary DelSite to Present at Investor Conference 2Health News:Medialink Features: The Painful Truth About Fibromyalgia 2Health News:Methodist Health System Foundation Announces Largest Single Gift 2Health News:Methodist Health System Foundation Announces Largest Single Gift 3Health News:Methodist Health System Foundation Announces Largest Single Gift 4Health News:Obesity common in children with heart disease 2
... Mikro-Tip pressure intravascular catheters provide a ... of measuring pressures in the heart ... Mikro-Tip catheters are ideal for high ... in size from 2 to 7 ...
... Millar Mikro-Tip pressure intravascular catheters provide ... method of measuring pressures in the ... thromboresistant Mikro-Tip catheters are ideal for ... range in size from 2 to ...
... Intravascular Mikro-Tip Pressure Catheters; Millar manufactures ... pressure sensor catheters for simultaneous high ... suitable for measuring pressure gradients across ... a vascular stenosis. The catheters are ...
... the United States dying from Sudden Cardiac Death ... recommended that AEDs be used as a standard ... Any AED can provide a life-saving shock during ... continuous monitoring capabilities during and after resuscitation. Plus ...
Medicine Products: